ICON plc Schedules Third Quarter 2024 Earnings Conference Call
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has announced its schedule for the third quarter 2024 earnings release and conference call. The company will:
1. Release financial results for Q3 2024 after market close on Wednesday, October 23, 2024.
2. Hold a conference call and webcast to discuss financial results and performance on Thursday, October 24, 2024, at 8:00am ET.
Any changes to the event and links to the live webcast will be posted on the Investor section of ICON's website under 'Events'. A webcast replay will be available approximately one hour after the call concludes.
ICON plc (NASDAQ: ICLR), un'importante organizzazione di ricerca clinica e intelligenza sanitaria, ha annunciato il programma per il rilascio dei risultati finanziari del terzo trimestre 2024 e la conference call. La società:
1. Pubblicherà i risultati finanziari per il Q3 2024 dopo la chiusura del mercato il mercoledì 23 ottobre 2024.
2. Terrà una conference call e una webcast per discutere i risultati finanziari e le performance il giovedì 24 ottobre 2024, alle 8:00 ET.
Eventuali modifiche all'evento e ai link per la webcast dal vivo saranno pubblicati nella sezione Investor del sito web di ICON sotto 'Eventi'. Una registrazione della webcast sarà disponibile circa un'ora dopo la conclusione della chiamata.
ICON plc (NASDAQ: ICLR), una organización líder en inteligencia sanitaria e investigación clínica, ha anunciado su programación para el lanzamiento de resultados del tercer trimestre de 2024 y la conferencia telefónica. La compañía:
1. Publicará los resultados financieros para el Q3 2024 después del cierre del mercado el miércoles 23 de octubre de 2024.
2. Realizará una conferencia telefónica y transmisión web para discutir los resultados financieros y el rendimiento el jueves 24 de octubre de 2024, a las 8:00 am ET.
Cualquier cambio en el evento y los enlaces a la transmisión web en vivo se publicarán en la sección de inversores del sitio web de ICON en 'Eventos'. Una grabación de la transmisión estará disponible aproximadamente una hora después de que finalice la llamada.
ICON plc (NASDAQ: ICLR)는 의료 정보 및 임상 연구의 선도적인 조직으로, 2024년 3분기 실적 발표 및 컨퍼런스 콜 일정을 발표했습니다. 회사는:
1. 2024년 10월 23일 수요일 시장 마감 후 2024년 3분기 재무 결과를 발표합니다.
2. 2024년 10월 24일 목요일, 오전 8시(ET)에 재무 결과 및 성과에 대해 논의하는 컨퍼런스 콜과 웹캐스트를 개최합니다.
이벤트에 대한 변경 사항과 라이브 웹캐스트 링크는 ICON 웹사이트의 투자자 섹션 '이벤트'에 게시됩니다. 콜 종료 약 1시간 후에 웹캐스트 재생이 가능합니다.
ICON plc (NASDAQ: ICLR), une organisation leader dans l'intelligence sanitaire et la recherche clinique, a annoncé son calendrier pour le lancement des résultats financiers du troisième trimestre 2024 et la conférence téléphonique. La société :
1. Publiera les résultats financiers pour le T3 2024 après la fermeture du marché le mercredi 23 octobre 2024.
2. Tiendra une conférence téléphonique et un webinaire pour discuter des résultats financiers et des performances le jeudi 24 octobre 2024 à 8h00 ET.
Tout changement concernant l'événement et les liens vers le webcast en direct sera publié dans la section Investisseurs du site d'ICON sous 'Événements'. Une rediffusion du webcast sera disponible environ une heure après la fin de l'appel.
ICON plc (NASDAQ: ICLR), eine führende Organisation für klinische Forschung und Gesundheitsintelligenz, hat ihren Zeitplan für die Ergebnisse des dritten Quartals 2024 und die Telefonkonferenz bekannt gegeben. Das Unternehmen wird:
1. Die Finanzergebnisse für das Q3 2024 nach Börsenschluss am Mittwoch, den 23. Oktober 2024 veröffentlichen.
2. Am Donnerstag, den 24. Oktober 2024 um 08:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse und die Leistung zu besprechen.
- None.
- None.
Any changes to this event and links to the live webcast will be posted on the Investor section of our website under “Events”. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20240927570445/en/
Kate Haven Vice President Investor Relations +1888 381 7923
Source: ICON plc
FAQ
When will ICON plc (ICLR) release its Q3 2024 earnings?
What time is ICON's (ICLR) Q3 2024 earnings conference call?
Where can I find information about ICON's (ICLR) Q3 2024 earnings webcast?
Will there be a replay available for ICON's (ICLR) Q3 2024 earnings call?
